MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

PLX-4720

CAS No. : 918505-84-7

MCE 站：PLX-4720

产品活性：PLX-4720 是一种有效的，选择性的 B-Raf^V600E 抑制剂，IC₅₀ 值为 13 nM；与对 c-Raf-1 的选择性相同，是野生型 B-Raf 选择性的 10 倍。

研究领域：MAPK/ERK Pathway

作用靶点：Raf

In Vitro: PLX-4720 displays >10 times selectivity against wild type B-Raf, ａnd >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, ａnd Aurora A with IC₅₀ of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-Raf^V600E with IC₅₀ of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-Raf^V600E oncogene, such as COLO205, A375, WM2664, ａnd COLO829 with GI₅₀ of 0.31 μM, 0.50 μM, 1.5 μM, ａnd 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest ａnd apoptosis exclusively in the B-Raf^V600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. PLX-4720 treatment (10 μM) significantly induces > 14-fold expression of BIM in the PTEN⁺ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis.

In Vivo: Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays ａnd regressions in B-Raf^V600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-Raf^V600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, ａnd dramatically decreases distant lung metastases.

相关产品：Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Oxygen Sensing Compound Library  |  Ferroptosis Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Doramapimod  |  GW 5074  |  Ro 5126766  |  AZ 628  |  GDC-0879  |  ZM 336372  |  Agerafenib  |  Raf inhibitor 1  |  AZ304  |  L-779450  |  MCP110  |  Raf inhibitor 2  |  Sorafenib (D3)

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。